Novolimus - Metabolite Drug
Novolimus is a metabolite of the drug Sirolimus, a novel mTOR inhibitor macrolytic lactone with anti-proliferative and anti-inflammatory properties developed by Elixir Medical. The macrocyclic lactone drugs represent the most widely utilized drug family for drug-eluting stent applications and have an established safety and efficacy profile.
-
Most popular related searches
Product Details
Novolimus and Sirolimus have been studied as part of Elixir Medical’s Clinical Programs. These clinical trials for DynamX™, DESyne®, DESyne® BD and the fully resorbable DESolve® and DESolve® Cx scaffolds have resulted in excellent clinical outcomes and sustained safety and effectiveness.
Customer reviews
No reviews were found for Novolimus - Metabolite Drug. Be the first to review!